
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is in a good financial position with a positive outlook and potential for future growth due to its successful product offerings and shift to the pharmacy channel, but there are risks to consider such as competition and patient switching. Additionally, the company's revenue is primarily derived from the US market and their pumps and disposable infusion sets, making it essential for them to continue their expansion into other developed countries and develop new product offerings to diversify their revenue streams.
Bears say
Tandem Diabetes Care is facing multiple challenges in increasing market share and profitability, including competition from Omnipod 5, potential delays in product development, and pressure from payors and CMS. The company has a strong desire to enter the tubeless/patch market, but early signals suggest that physicians are not yet fully convinced of the benefits. Additionally, the company's decision to transition to a pay-as-you-go model and direct sales in certain markets may result in revenue headwinds in the short term, with moderate growth expected in the long term.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares